Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy

The Pharmacogenomics Journal volume 14, pages 418–423 (2014)Cite this article

Subjects

Abstract

In gastric cancer, available clinical studies focusing on the activated hepatocyte growth factor (HGF)/MET pathway are limited to surgical and often heterogeneous series. MET copy number gain (CNG) and an activating truncation in the HGF promoter (deoxyadenosine tract element, DATE+) were studied in tumors of 95 patients with advanced gastric cancer treated with palliative chemotherapy. Associations with overall survival (OS) and the pattern of metastatic disease were studied. Median OS was 9.7 months in 80 MET CNG <5 copies cases (MET−), and 6.4 months in 15 MET CNG was ⩾5 copies cases (MET+) (P=0.001). MET+ status confirmed the adverse prognostic effect in the multivariate model. A significantly different distribution of MET+/DATE+ and MET−/DATE− cases was observed between patients with and without peritoneal carcinomatosis (PC). MET+ status confirms its adverse prognostic role in advanced gastric cancer patients. The activated MET/HGF axis seems to be associated with PC. These findings are relevant to the development of anti-MET/HGF compounds.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Trusolino L, Bertotti A, Comoglio PM . MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834–848.

    Article  CAS  PubMed  Google Scholar 

  2. Peters S, Adjei AA . MET: a promising anticancer therapeutic target. Nat Rev Clin Oncol 2012; 9: 314–326.

    Article  CAS  PubMed  Google Scholar 

  3. Niemann HH . Structural insights into Met receptor activation. Eur J Cell Biol 2011; 90: 972–981.

    Article  CAS  PubMed  Google Scholar 

  4. Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA . Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol 2013; 10: 643–655.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Yu S, Yu Y, Zhao N, Cui J, Li W, Liu T . c-Met as a prognostic marker in gastric cancer: a systematic review and meta-analysis. PLoS ONE 2013; 8: e79137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lennerz JK, Kwak EL, Ackerman A, Michael M, Fox SB, Bergethon K et al. MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol 2011; 29: 4803–4810.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Catenacci DV, Henderson L, Xiao SY, Patel P, Yauch RL, Hegde P et al. Durable complete response of metastatic gastric cancer with anti-Met therapy followed by resistance at recurrence. Cancer Discov 2011; 1: 573–579.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 2011; 29: 1271–1279.

    Article  CAS  PubMed  Google Scholar 

  9. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC et al. Evaluation of MET pathway biomarkers in a phase II study of rilotumumab (R, AMG 102) or placebo (P) in combination with epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) with locally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 2012; 30 (Suppl): (abstract 4005).

    Google Scholar 

  10. Catenacci DV, Cervantes G, Yala S, Nelson EA, El-Hashani E, Kanteti R et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 2011; 12: 9–46.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Toiyama Y, Yasuda H, Saigusa S, Matushita K, Fujikawa H, Tanaka K et al. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer. Int J Cancer 2012; 130: 2912–2921.

    Article  CAS  PubMed  Google Scholar 

  12. Zhao L, Yasumoto K, Kawashima A, Nakagawa T, Takeuchi S, Yamada T et al. Paracrine activation of MET promotes peritoneal carcinomatosis in scirrhous gastric cancer. Cancer Sci 2013; 104: 1640–1646.

    Article  CAS  PubMed  Google Scholar 

  13. Park WS, Oh RR, Kim YS, Park JY, Shin MS, Lee HK et al. Absence of mutations in the kinase domain of the Met gene and frequent expression of Met and HGF/SF protein in primary gastric carcinomas. APMIS 2000; 108: 195–200.

    Article  CAS  PubMed  Google Scholar 

  14. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer 2012; 107: 325–333.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS et al. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011; 25: 1517–1524.

    CAS  PubMed  Google Scholar 

  16. Ha SY, Lee J, Kang SY, DO IG, Ahn S, Park JO et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol 2013; 26: 1632–1641.

    Article  CAS  PubMed  Google Scholar 

  17. Graziano F, Galluccio N, Lorenzini P, Ruzzo AM, Canestrari E, D’Emidio S et al. Genetic activation of the MET pathway and prognosis of patients with high-risk, radically resected gastric cancer. J Clin Oncol 2011; 29: 4789–4795.

    Article  CAS  PubMed  Google Scholar 

  18. Ma J, Defrances MC, Zou C, Johnson C, Ferrell R, Zamegar R . Somatic mutation and functional polymorphism of a novel regulatory element in the HGF gene promoter causes its aberrant expression in human breast cancer. J Clin Invest 2009; 119: 478–491.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Catalano V, Graziano F, Santini D, D’Emidio S, Baldelli AM, Rossi D et al. Second-line chemotherapy for patients with advanced gastric cancer: who may benefit? Br J Cancer 2008; 99: 1402–1407.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mallett S, Timmer A, Sauerbrei W, Altman DG . Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer 2010; 102: 173–180.

    Article  CAS  PubMed  Google Scholar 

  21. Han SU, Lee HY, Lee JH, Kim WH, Nam H, Kim H et al. Modulation of E-cadherin by hepatocyte growth factor induces aggressiveness of gastric carcinoma. Ann Surg 2005; 242: 676–683.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Jiang WG, Davies G, Martin TA, Parr C, Mason MD, Jenkins SA et al. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int J Mol Med 2005; 16: 723–728.

    CAS  PubMed  Google Scholar 

  23. Trusolino L, Cavassa S, Angelini P, Andò M, Bertotti A, Comoglio PM et al. HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. FASEB J 2000; 14: 1629–1640.

    Article  CAS  PubMed  Google Scholar 

  24. Crouch S, Spidel CS, Lindsey JS . HGF and ligation of alphavbeta5 integrin induce a novel, cancer cell-specific gene expression required for cell scattering. Exp Cell Res 2004; 292: 274–287.

    Article  CAS  PubMed  Google Scholar 

  25. Hartgrink HH, Jansen EP, van Grieken NC, van de Velde CJ . Gastric cancer. Lancet 2009; 374: 477–490.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Catenacci D, Henderson L, Liao W, Burrows J, Hembrough T . KRAS gene amplification defines a distinct molecular subgroup of gastroesophageal adenocarcinoma that may benefit from combined anti-MET/AKT therapy. AACR 2012 Breakthroughs in Basic and Translational Cancer Research Maui Hawai. Cancer Res 2013, (abstract 141239).

  27. Hembrough T, Liao W, Henderson L, Xu P, Burrows J, Catenacci D . Development of a quantitative gastroesophageal cancer selected reaction monitoring mass spectrometric multi-plex assay for use in FFPE tumor tissues. Proceedings of 24th EORTC-NCI-AACR Symposium.. Eur J Cancer 2012; 48 (Suppl 6): 172 (abstract 561).

    Google Scholar 

  28. Cepero V, Sierra JR, Corso S, Ghiso E, Casorzo L, Perera T et al. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors. Cancer Res 2010; 70: 7580–7590.

    Article  CAS  PubMed  Google Scholar 

  29. Catenacci DVT, Polite B, Henderson L, Peng Xu, Rambo B, Liao WL et al. Towards personalized treatment for gastroesophageal adenocarcinoma (GEC): Strategies to address tumor heterogeneity—PANGEA. 2014 ASCO Gastrointestinal Cancer Symposium. J Clin Oncol 2014; 32 (Suppl 3): (abstract 66).

    Article  Google Scholar 

  30. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE . Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 2006; 24: 2903–2909.

    Article  CAS  PubMed  Google Scholar 

  31. Kim HS, Kim HJ, Kim SY, Kim TY, Lee KW, Baek SK et al. Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis. Ann Oncol 2013; 24: 2850–2854.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Onco-Hematology, Division of Medical Oncology, Azienda Ospedaliera ‘Ospedali Riuniti Marche Nord’, Pesaro, Italy

    F Graziano, V Catalano, D Sarti & G Fiorentini

  2. Department of Histopathology, Azienda Ospedaliera ‘Ospedali Riuniti Marche Nord’, Pesaro, Italy

    P Lorenzini & M De Nictolis

  3. Department of Biomolecular Sciences, University of Urbino ‘Carlo Bo’, Urbino, Italy

    E Giacomini, M Magnani & A Ruzzo

Authors
  1. F Graziano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. V Catalano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Lorenzini
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E Giacomini
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. D Sarti
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Fiorentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M De Nictolis
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Magnani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A Ruzzo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F Graziano.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Graziano, F., Catalano, V., Lorenzini, P. et al. Clinical impact of the HGF/MET pathway activation in patients with advanced gastric cancer treated with palliative chemotherapy. Pharmacogenomics J 14, 418–423 (2014). https://doi.org/10.1038/tpj.2014.11

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/tpj.2014.11

This article is cited by

Search

Advanced search

Quick links